GlassScriptPhysician profile
Shane O Summers
NPI 1497751671
$4,385.74
in general payments reported to CMS, 2019-2025
45 companies · $1,122 in 2025
The $1,122 reported for 2025 was more than what 88% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $509 · 2020: $473 · 2021: $381 · 2022: $613 · 2023: $602 · 2024: $686 · 2025: $1,122.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,410.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,409.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $432.03 | 2019-2025 | Rybelsus, Ozempic |
| Abbvie INC. | $354.63 | 2020-2025 | Vraylar |
| Glaxosmithkline, LLC. | $312.28 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Astrazeneca Pharmaceuticals LP | $303.04 | 2020-2025 | Farxiga, Breztri, Airsupra |
| Janssen Pharmaceuticals, INC | $276.63 | 2019-2024 | Xarelto |
| Supernus Pharmaceuticals, INC. | $251.17 | 2019-2021 | |
| Pfizer INC. | $243.58 | 2019-2025 | |
| Astellas Pharma US INC | $196.35 | 2019-2025 | Veozah |
| Lilly USA, LLC | $194.51 | 2020-2025 | Mounjaro, Zepbound, Jardiance |
| Takeda Pharmaceuticals U.S.A., INC. | $178.88 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $150.59 | 2021-2025 | |
| Abbott Laboratories | $118.56 | 2021-2025 | Freestyle Libre 3, Eterna |
| Dexcom, INC. | $113.90 | 2023-2025 | Dexcom G6 Transmitter |
| Boehringer Ingelheim Pharmaceuticals, INC. | $111.81 | 2020-2025 | Jardiance |
| Axsome Therapeutics, INC. | $98.49 | 2024-2025 | Auvelity, Symbravo |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shane Summers listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.